Outlook Therapeutics to Present at Major Investment Conference
Outlook Therapeutics to Present at Major Investment Conference
ISELIN, N.J. — Outlook Therapeutics, Inc. (NASDAQ: OTLK), a biopharmaceutical firm making strides in ophthalmic treatments, is set to present at the H.C. Wainwright 26th Annual Global Investment Conference taking place in New York. The conference, scheduled from September 9 to 11, 2024, serves as a prominent platform for companies to showcase their innovations and connect with investors.
Presentation Highlights
Russell Trenary, the President and CEO of Outlook Therapeutics, will take the stage to discuss the company’s advancements, particularly its groundbreaking ophthalmic formulation of bevacizumab aimed at treating wet age-related macular degeneration (wet AMD). This formulation, LYTENAVA™ (bevacizumab gamma), is the first of its kind to gain regulatory approval in the European Union and the United Kingdom, marking a significant achievement in the field of retinal therapies.
Engagement Opportunities
In addition to the presentation, the management team will be available for individual meetings with registered investors. This is a crucial opportunity for stakeholders to engage directly and discuss prospects with the company’s leadership, fostering deeper understanding of its mission and progress in developing life-changing therapies.
Webcast Availability
A video webcast of the presentation will be available for on-demand viewing starting on September 9, 2024. This will allow further accessibility for those unable to attend the live event. The session can be streamed from the company’s Events page and will remain archived for 90 days, ensuring that all interested parties can catch up on the insights shared during the conference.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is dedicated to delivering innovative solutions for retinal diseases like wet AMD through its investigational product, ONS-5010/LYTENAVA™. Following its approval in the EU and UK, the company is gearing up for a commercial launch expected in the first half of 2025. In the United States, this product is still under evaluation, with the intent to submit a Biologics License Application (BLA) pending the results of ongoing studies. If successful, this could pave the way for the first approved ophthalmic formulation of bevacizumab for retinal use in the United States.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
Email: OTLK@jtcir.com
Frequently Asked Questions
What is the purpose of the H.C. Wainwright conference?
The conference provides companies like Outlook Therapeutics a platform to present their latest developments and connect with potential investors.
What is LYTENAVA™?
LYTENAVA™ (bevacizumab gamma) is an ophthalmic formulation approved for treating wet AMD, representing a major advancement in retinal therapies.
When will the presentation be available for viewing?
The presentation will be available on-demand from September 9, 2024, and accessible for 90 days afterwards.
Who will be presenting at the conference?
Russell Trenary, the President and CEO of Outlook Therapeutics, will be representing the company at the event.
What are the future plans for Outlook Therapeutics?
The company aims to initiate the commercial launch of LYTENAVA™ in the EU and UK in the first half of 2025 while evaluating its other investigational products in the U.S.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Super Micro Computer Responds to Hindenburg's Allegations
- Equature's 2024.3 Software Revolutionizes Public Safety Operations
- Jamie Foxx Brings Humor to BetMGM's 2024 Football Campaign
- Wipfli Unveils 2024 Annual Report Detailing Growth and Innovation
- Autonomous Cars Forecast: Growth to USD 43.44 Billion By 2032
- Investing Insights: Nvidia Versus Arm Holdings in AI Sector
- Agmatix Unveils RegenIQ: Revolutionizing Regenerative Agriculture
- BoomerangFX Expands Innovative Solutions in Asia and Latin America
- Trethom AS Reduces Major Shareholding in Vow ASA Below 5%
- Costco to Expand with Four New Locations by End of 2024
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- BCFNJC's What We Heard Report from First Nations Justice Forum
- Asia Pacific Wireless Earphones Market Expected to Thrive
- Cork Packaging Market Expected to Hit USD 2.7 Billion Growth
- MICE Industry Expected to Reach $1,337 Billion by 2033
- Packaging Automation Market Growth Driven by E-commerce Boom
- Status of Audit for Aktsiaselts Silvano Fashion Group Revealed
- Tiny Traveler Unveils Advanced AI Baby Monitor for Parents
- Portable Projector Market Growth Projections: $2.1 Billion by 2029
- Celebrate the Festive Season at The Ocean Club, Bahamas
- Ethical AI Transformation: The P&C Insurance Industry's Role
- HomeSafe Alliance Achieves Milestone Of 100 Military Moves
- Xiaohongshu's Street Life Festival Draws Record Attendance and Engagement
- Starlight Children's Foundation Celebrates Childhood Cancer Month
- Sandals Resorts Partners with Leo Burnett for Creative Vision
Recent Articles
- Aker ASA Finalizes Aker BioMarine Feed Ingredients Deal
- Exploring the Event Logistics Market Growth to USD 87.8 Billion
- Constellation Brands Adjusts Earnings Outlook for 2025
- Allpowers Showcases Innovative Power Solutions at IFA 2024
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Semnur Pharmaceuticals and Denali Capital Announce Merger
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- AGBA and Triller Finalize Amended Merger Agreement Details
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- Haivision MCS Secures $61.2M Contract with US Navy for Video Systems
- Huddle House Launches MVP Waffle Tacos to Delight Guests
- Growth of Medical Tourism Market Forecast to USD 207.5 Billion
- The Chefs' Warehouse Engages in CL King's Best Ideas Conference
- Diverse Perspectives of Fed Policymakers on Rate Cuts
- Bicara Therapeutics Pursues IPO for Innovative Cancer Treatments
- Forward Therapeutics Appoints Ulrich Thienel as CMO
- Unicycive Therapeutics Submits NDA for Oxylanthanum Carbonate
- Regenx Tech Corp Announces Production Update and Webinar
- iBio Leaders Set to Speak at Major Investor Conferences
- Recor Medical Supports New ESC Guidelines for Hypertension Management
- NextEra Energy Announces Investor Meetings for September 2024
- Calliditas Therapeutics' Strategic Response to Asahi Kasei's Move
- Blackwell 3D Advances Corporate Growth and Asian Expansion Plans
- Pakistan's PM Focuses on IMF Loan Program Completion Steps